Key Drivers
- Improving Margins
- Negative Equity
- Positive Cash Flow
AIAI Summary
Chemours is now a leveraged recovery play rather than an immediate PFAS-survival story, but investors should wait for sustained free cash flow and deleveraging to validate that accrued, long-dated liabilities can be managed amid weak demand and negative equity.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Improving Margins
- •Negative Equity
- •Positive Cash Flow
CC shows improving margins and positive cash flow, but deepening losses, negative equity, and high leverage make its low sales-based valuation highly risky.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support test
- •Oversold momentum
CC remains bearish after a ~10% decline over the last month, with $14.30–$14.50 support under pressure and a rebound requiring a move above $14.70 to improve momentum.
Approximately 10% decline over the last month
Sentiment & News
Key News Insights:
- •BlackRock Stake
- •PFAS Settlement
- •Shares Rise
Chemours gained 7.5% amid BlackRock's sizable stake disclosure, though PFAS litigation and settlement liabilities remain key risks.
The stock's momentum may be tempered by continuing PFAS-related legal and financial uncertainty
Similar Companies in Basic Materials
Other companies in the same sector with AI ratings